Home / Resources / Pink Sheet Podcast: BIOSECURE Act Advances, Trial Diversity Sticks & More

Pink Sheet Podcast: BIOSECURE Act Advances, Trial Diversity Sticks & More

Podcast
Commercial
Pink Sheet Podcast Logo

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, and Interim Editor in Chief Nielsen Hobbs discuss the implications of the BIOSECURE Act on the pharma industry in the US and China, as well as other hot topics.

It seems like there’s a lot of level setting the FDA and Congress are going to have to do here.
Pink Sheet reporter, Sarah Karlin-Smith
Related products
Lab professionals conducting research using informed decisions from Pink Sheet insights.
Pink Sheet
The leader in pharmaceutical news and regulatory trend analysis
Citeline subscriber exploring the diversity feasibility using Global Patient Insights.
Global Patient Insights
Enabling sponsors to optimize investigator selection and hit diversity goals faster
Blocks showing the network behind the Patient Recruitment Collective, speeding up the process of patients to their trials.
Citeline Connect Marketplace
A robust recruitment network of 100+ recruitment organizations powering more efficient, effective trial enrollment

Related resources

''
OCT 30, 2024
Article
Regulatory & Compliance

Artificial Intelligence Regulation

Drug sponsors strive to make the best use of artificial intelligence, but doing so requires understanding where health authorities are drawing the lines. Download a sample of our coverage from the US, Europe, and Asia of the emerging framework for AI regulation.

Cover for Scrip Asia 100: Innovating For A Global Future report
OCT 29, 2024
Report
Commercial

Scrip Asia 100: Innovating for a Global Future

Each year we analyze the top 100 companies and the key trends shaping the APAC’s future. This is your go-to resource for navigating the complexities of this crucial market.

OCT 30, 2024
Article
Regulatory & Compliance

EU’s Pharma Legislative Reform

Every drug sponsor wants to make the best use of Artificial Intelligence, but doing so requires understanding where health authorities are drawing the lines. Download a sample of our coverage from Asia, Europe and the United States of the emerging framework for AI regulation.

View all